PAPER Saijo E, Scheff SW, Telling GC
SEARCH RESULTS
331254 RESULTS
PAPER Malpass K
MRI may predict the onset of Alzheimer disease.
Nat Rev Neurol. 2011 Jun;7(6):302. PubMed: 21654711Jadie Anderson
United States
John Breitner on Feeding Frenzy—Therapeutics Tap Tryptophan, Cathepsins, HDACs, Zinc
COMMENT The primary outcome data from the reaZin study appear to be consistent with the proposed action of the intervention. The three cognitive and functional measures used for the series of secondary outcomes are appropriate, but the small size of the sample me
M. Flint Beal on Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration.
COMMENT This is an interesting study that examined the neuroprotective efficacy of JM6, a small molecule inhibitor of kynurenine 3-monooxygenase (KMO). The authors demonstrate that oral administration of JM6 inhibits KMO in the blood, resulting in an increase in
Penny Hallett on Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration.
COMMENT In the Cell paper by Zwilling et al. on oral kynurenine 3-monooxygenase (KMO) inhibition in Huntington's and Alzheimer's transgenic mouse models, a striking effect was the prevention of pre-synaptic protein loss in the transgenic models of AD (A
Marianna Siapera
Aristotle University of ThessalonikiGreece
Li Gan on The cysteine protease inhibitor, E64d, reduces brain amyloid-β and improves memory deficits in Alzheimer's disease animal models by inhibiting cathepsin B, but not BACE1, β-secretase activity.
COMMENT Aβ-lowering effects of E64d are very intriguing. However, since E64d inhibits numerous cathepsins, the mechanism by which E64d lowers Aβ remains unclear. Moreover, given the recent finding from Randy Nixon's group that inhibitors of cathepsins, inclu
PAPER Barrett AJ, Kembhavi AA, Brown MA, Kirschke H, Knight CG, Tamai M, Hanada K
L-trans-Epoxysuccinyl-leucylamido(4-guanidino)butane (E-64) and its analogues as inhibitors of cysteine proteinases including cathepsins B, H and L.
Biochem J. 1982 Jan 1;201(1):189-98. PubMed: 7044372Jack de la Torre
University of Texas at AustinAustin, United States
PAPER Tang W, Lu Y, Tian QY, Zhang Y, Guo FJ, Liu GY, Syed NM, Lai Y, Lin EA, Kong L, Su J, Yin F, Ding AH, Zanin-Zhorov A, Dustin ML, Tao J, Craft J, Yin Z, Feng JQ, Abramson SB, Yu XP, Liu CJ
The growth factor progranulin binds to TNF receptors and is therapeutic against inflammatory arthritis in mice.
Science. 2011 Apr 22;332(6028):478-84. PubMed: 21393509PAPER Satoyoshi E
Therapeutic trials on progressive muscular dystrophy.
Intern Med. 1992 Jul;31(7):841-6. PubMed: 1450492PAPER Heyes MP, Saito K, Crowley JS, Davis LE, Demitrack MA, Der M, Dilling LA, Elia J, Kruesi MJ, Lackner A
Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease.
Brain. 1992 Oct;115 ( Pt 5):1249-73. PubMed: 1422788Penny Hallett
McLean Hospital/Harvard Medical SchoolUnited States
PAPER Vécsei L, Miller J, MacGarvey U, Beal MF
Kynurenine and probenecid inhibit pentylenetetrazol- and NMDLA-induced seizures and increase kynurenic acid concentrations in the brain.
Brain Res Bull. 1992 Feb;28(2):233-8. PubMed: 1596743Current Filters
No filters selected